Latest Insider Transactions at Regenxbio Inc. (RGNX)
This section provides a real-time view of insider transactions for Regenxbio Inc. (RGNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of REGENXBIO Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of REGENXBIO Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2022
|
Jennifer Zachary |
BUY
Grant, award, or other acquisition
|
Direct |
6,020
+50.0%
|
-
|
|
Jan 20
2022
|
Vittal Vasista Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,900
+15.55%
|
$0
$0.85 P/Share
|
|
Jan 03
2022
|
Vittal Vasista Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,900
+6.29%
|
-
|
|
Jan 03
2022
|
Kenneth T. Mills |
BUY
Grant, award, or other acquisition
|
Direct |
35,796
+10.36%
|
-
|
|
Jan 03
2022
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,900
+25.62%
|
-
|
|
Jan 03
2022
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,700
+26.9%
|
-
|
|
Jan 03
2022
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,900
+34.17%
|
-
|
|
Jan 03
2022
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,598
-16.23%
|
$52,734
$33.75 P/Share
|
|
Jan 03
2022
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,700
+28.29%
|
-
|
|
Jan 01
2022
|
Kenneth T. Mills |
SELL
Payment of exercise price or tax liability
|
Direct |
3,636
-1.31%
|
$116,352
$32.7 P/Share
|
|
Jan 01
2022
|
Patrick J. Christmas Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,332
-8.14%
|
$42,624
$32.7 P/Share
|
|
Jan 01
2022
|
Olivier Danos Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,221
-6.23%
|
$39,072
$32.7 P/Share
|
|
Jan 01
2022
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,152
-10.47%
|
$36,864
$32.7 P/Share
|
|
Jan 01
2022
|
Curran Simpson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,332
-7.51%
|
$42,624
$32.7 P/Share
|
|
Dec 31
2021
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1
+0.01%
|
$27
$27.8 P/Share
|
|
Dec 23
2021
|
Allan M. Fox |
SELL
Open market or private sale
|
Indirect |
51,231
-1.63%
|
$1,793,085
$35.38 P/Share
|
|
Dec 22
2021
|
Allan M. Fox |
SELL
Open market or private sale
|
Indirect |
61,638
-3.75%
|
$2,095,692
$34.4 P/Share
|
|
Dec 02
2021
|
Kenneth T. Mills |
SELL
Bona fide gift
|
Direct |
3,300
-1.17%
|
-
|
|
Nov 08
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
1,500
-0.53%
|
$60,000
$40.0 P/Share
|
|
Nov 08
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.53%
|
$4,500
$3.76 P/Share
|
|
Sep 27
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
1,500
-0.53%
|
$63,000
$42.19 P/Share
|
|
Sep 27
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.53%
|
$4,500
$3.76 P/Share
|
|
Sep 17
2021
|
Allan M. Fox |
SELL
Open market or private sale
|
Indirect |
48,233
-3.41%
|
$2,170,485
$45.04 P/Share
|
|
Sep 14
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
35,000
-11.08%
|
$1,575,000
$45.11 P/Share
|
|
Sep 14
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+5.06%
|
$70,000
$2.31 P/Share
|
|
Sep 13
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
3,000
-1.06%
|
$120,000
$40.02 P/Share
|
|
Sep 13
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+1.05%
|
$9,000
$3.76 P/Share
|
|
Jul 27
2021
|
Vittal Vasista Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.48%
|
$0
$0.85 P/Share
|
|
Jun 30
2021
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
555
+2.75%
|
$18,315
$33.02 P/Share
|
|
Jun 25
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
1,500
-0.53%
|
$60,000
$40.25 P/Share
|
|
Jun 25
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.53%
|
$4,500
$3.76 P/Share
|
|
Jun 24
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
4,500
-1.58%
|
$180,000
$40.02 P/Share
|
|
Jun 24
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+1.55%
|
$13,500
$3.76 P/Share
|
|
Feb 25
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
1,500
-0.53%
|
$60,000
$40.77 P/Share
|
|
Feb 25
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.53%
|
$0
$0.85 P/Share
|
|
Feb 12
2021
|
Patrick J. Christmas Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,701
-22.31%
|
$230,349
$49.08 P/Share
|
|
Feb 12
2021
|
Patrick J. Christmas Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,701
+18.24%
|
$56,412
$12.1 P/Share
|
|
Feb 08
2021
|
Patrick J. Christmas Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,300
-7.36%
|
$63,700
$49.11 P/Share
|
|
Feb 08
2021
|
Patrick J. Christmas Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+6.85%
|
$15,600
$12.1 P/Share
|
|
Feb 02
2021
|
Patrick J. Christmas Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-19.49%
|
$440,000
$44.95 P/Share
|
|
Feb 02
2021
|
Patrick J. Christmas Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+27.49%
|
$120,000
$12.1 P/Share
|
|
Jan 25
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
6,500
-0.76%
|
$279,500
$43.89 P/Share
|
|
Jan 25
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+2.21%
|
$0
$0.85 P/Share
|
|
Jan 15
2021
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
252
-0.22%
|
$12,600
$50.04 P/Share
|
|
Jan 14
2021
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,093
-8.88%
|
$554,650
$50.03 P/Share
|
|
Jan 14
2021
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,612
-39.55%
|
$580,600
$50.01 P/Share
|
|
Jan 14
2021
|
Curran Simpson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,612
+16.12%
|
$313,524
$27.65 P/Share
|
|
Jan 12
2021
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,200
-3.25%
|
$210,000
$50.01 P/Share
|
|
Jan 12
2021
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,700
-8.74%
|
$85,000
$50.03 P/Share
|
|
Jan 12
2021
|
Curran Simpson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+8.04%
|
$32,300
$19.5 P/Share
|